A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Phase 2 Completed 327 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

Timeline

Start: 2021-09-16
Primary completion: 2024-07-09
Completion: 2025-05-22

Outcome

Missed primary endpoint

registry Posterior Mean Difference 1.68 (95% CI -0.375 to 3.771) NCT05063539 ↗

registry Posterior Mean Difference -3.20 (95% CI -5.354 to -1.042) NCT05063539 ↗

paper no clinically meaningful benefit vs placebo was observed for the primary end point (iADRS score) at 100 weeks PMID 42441396 ↗

Publications

Fleisher AS, Munsie L, Mancini M, Cheng YJ, Guo J, Nuthall H, Otero DS, Kotari V, Kielbasa W, Hutton M, Brys M, Mergott DJ, Mintun M, Hansson O. Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial. JAMA. 2026 Jul 13. doi: 10.1001/jama.2026.12768. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ceperognastat	Small molecule	0.75 mg	Oral
Subject	ceperognastat	Small molecule	3 mg	Oral